A Thematic Analysis of Attitudes Toward Changes to Cervical Screening in Australia

Background In December 2017, the Australian National Cervical Screening Program (NCSP) was changed to encompass a 5-yearly human papillomavirus (HPV) primary test for women aged 25 to 74 years. Public concerns about changes to screening programs has been demonstrated in other countries previously. Objective The aim of the study was to explore in depth women’s understanding of and concerns about the specific changes to the Australian NCSP implemented in December 2017. Methods A Web-based petition (Change.org) opposing the changes received over 70,000 signatures and nearly 20,000 comments from February to March 2017. Of 19,633 comments, a random sample of 10% (2000/19,633) were analyzed using content analysis (reported elsewhere). Comments relating directly to the specific changes to the program were further analyzed using qualitative thematic analysis. Results Around one-third (34.55%; 691/2000) of the total comments were related to concerns about specific changes to the program. The greatest concern was that screening intervals would be too long and that cancer may not be detected in time for successful treatment. Missing cancer in younger women (aged <25 years) was also an important concern, perceiving younger women to remain at significant risk. Notably, concern was rarely expressed about the new test (the HPV test). Conclusions Gaps in knowledge and understanding about changes to the program and the rationale behind these have caused health concerns among women. Worry about the extended screening interval indicates little understanding of the slow progression of the HPV infection to cervical cancer or the high rates of regression. Identification of these knowledge gaps can inform both deintensification of other cancer screening programs and practitioners, so that they are able to address these concerns with their patients.

[1]  Giri N. K. Rangan,et al.  Committee , 2019, 2019 International Conference on Radar, Antenna, Microwave, Electronics, and Telecommunications (ICRAMET).

[2]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[3]  C. Bonner,et al.  ‘It has saved thousands of lives, so why change it?’ Content analysis of objections to cervical screening programme changes in Australia , 2018, BMJ Open.

[4]  R. Moynihan,et al.  Mapping the drivers of overdiagnosis to potential solutions , 2017, British Medical Journal.

[5]  M. A. Gerend,et al.  Understanding women's hesitancy to undergo less frequent cervical cancer screening. , 2017, Preventive medicine.

[6]  E. Franco,et al.  Correlates of women’s intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval , 2016, BMC Public Health.

[7]  S. Garland,et al.  Primary HPV DNA based cervical cancer screening at 25 years: Views of young Australian women aged 16-28 years. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[8]  S. Garland,et al.  Clinicians' attitude towards changes in Australian National Cervical Screening Program. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  A. Burke,et al.  Patient Concerns About Human Papillomavirus Testing and 5-Year Intervals in Routine Cervical Cancer Screening , 2015, Obstetrics and gynecology.

[10]  L. Sharp,et al.  “If you can’t treat HPV, why test for it?” Women’s attitudes to the changing face of cervical cancer prevention: a focus group study , 2014, BMC Women's Health.

[11]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[12]  D. Manninen,et al.  Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers. , 2013, Preventive medicine.

[13]  J. Schulkin,et al.  Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists. , 2013, American journal of preventive medicine.

[14]  E. Franco,et al.  Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial – the HPV FOCAL Study , 2012, British Journal of Cancer.

[15]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[16]  J. Hay,et al.  Awareness of the 2009 US Preventive Services Task Force recommended changes in mammography screening guidelines, accuracy of awareness, sources of knowledge about recommendations, and attitudes about updated screening guidelines in women ages 40–49 and 50+ , 2012, BMC Public Health.

[17]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[18]  B. Magee,et al.  Attitudes of women in their forties toward the 2009 USPSTF mammogram guidelines: a randomized trial on the effects of media exposure. , 2011, American journal of obstetrics and gynecology.

[19]  Jasmin A. Tiro,et al.  Too Much of a Good Thing? Physician Practices and Patient Willingness for Less Frequent Pap Test Screening Intervals , 2010, Medical care.

[20]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[21]  Lisa M. Schwartz,et al.  Screening for cervical cancer: will women accept less? , 2005, The American journal of medicine.

[22]  S. Rolnick,et al.  Impact of a new cervical pap smear screening guideline on member perceptions and comfort levels. , 1999, Preventive medicine.

[23]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[24]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.